In several subpopulations of women, a type of cervical cancer that is less amenable to Pap testing is increasing, pointing to the growing importance of human papillomavirus (HPV) testing and vaccination. The study appears early online in Preventive Medicine.
Overall trends in cervical cancer incidence have been driven by declines in squamous cell carcinoma, which account for the majority of cervical cancers. Most of the rest are adenocarcinomas, for which Pap testing is less sensitive. While overall cervical cancer rates have been dropping for decades, cervical adenocarcinomas seem to have become more common in the past 20 to 30 years. But there has been limited reporting on recent trends.
To learn more, investigators led by Farhad Islami, MD, PhD, analyzed recent cervical cancer incidence trends by histology and age in the United States. They examined trends in squamous cell carcinoma and adenocarcinoma incidence rates in the U.S. by age group, race/ethnicity, and stage at diagnosis using data from the U.S. Cancer Statistics Incidence Analytic Database.
The authors state that "more efforts are needed to increase screening utilization according to guidelines and appropriate follow-up of positive results" to further reduce the burden of cervical cancer. They note that increasing the use of HPV testing may improve early detection of adenocarcinoma, but they also recommend research to further improve screening strategies to reduce overdiagnosis, which may be more common with HPV testing. HPV vaccination is an effective tool to prevent cervical cancer because virtually all these cancers are caused by HPV infection. "Our results also underscore the importance of HPV vaccination. Concerted efforts are needed to increase its use, which remains suboptimal" said Dr. Islami.